Quality standards for preclinical research in cardio-oncology

Preclinical research in cancer therapy-related cardiovascular toxicity (CTR-CVT) is a major domain of cardio-oncology and has provided biological explanation for the cardiovascular adverse effects of many cancer therapies. However, the choice of the experimental models to investigate the mechanisms of CTR-CVT is often based on personal experience and opinion, rather than on established principles and available evidence. Moreover, presentation of methods and results is frequently approximate. This Scientific Statement outlines potential quality standards regarding methodology and reporting in preclinical cardio-oncology research, with the goal of promoting accurate, reliable, and reproducible studies. Quality standards are distinguished in first-tier, when considered essential for robustness unless there is a strong justification for their omission, and second-tier standards, when desirable, but not necessary. First-tier standards ensure credible, self-sustaining research, while second-tier ones enhance quality of investigations and accelerate understanding of CTR-CVT. Adherence to the proposed quality standards is expected to benefit researchers embarking on new investigations, facilitate funding allocation, and inform the development of novel oncological therapies, eventually moving cardio-oncology science forward.

Authors

Institutions

Publication Details

Journal
European Heart Journal
Published
2026-09-07
DOI
https://doi.org/10.1093/eurheartj/ehag609
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Quality standards for preclinical research in cardio-oncology

Giorgio Minotti, Johann Wojta, Pilar Martı́n, Pietro Ameri et al.
European Heart Journal
Chemotherapy-induced cardiotoxicity and mitigation
article

Quality standards for preclinical research in cardio-oncology

Giorgio Minotti, Johann Wojta, Pilar Martı́n, Pietro Ameri, Ioannis I. Verginadis, Carol Ann Remme, Alessandra Ghigo, June‐Wha Rhee, Zoltán V. Varga, Carlo G. Tocchetti, Éric Morel, Gerard Walls, Ambra Costa, Carolina Balbi, Wouter C. Meijers, Aarti Asnani, Paul C. Evans, Paul W. Burridge, Gilles W. De Keulenaer, Ioanna Andreadou, Doan Ngo, Teresa López Fernández, Rosalinda Madonna, Borja Ibáñez, Uri Amit, Peter van Der Meer, Lorenz H Lehmann
article en

Abstract

Preclinical research in cancer therapy-related cardiovascular toxicity (CTR-CVT) is a major domain of cardio-oncology and has provided biological explanation for the cardiovascular adverse effects of many cancer therapies. However, the choice of the experimental models to investigate the mechanisms of CTR-CVT is often based on personal experience and opinion, rather than on established principles and available evidence. Moreover, presentation of methods and results is frequently approximate. This Scientific Statement outlines potential quality standards regarding methodology and reporting in preclinical cardio-oncology research, with the goal of promoting accurate, reliable, and reproducible studies. Quality standards are distinguished in first-tier, when considered essential for robustness unless there is a strong justification for their omission, and second-tier standards, when desirable, but not necessary. First-tier standards ensure credible, self-sustaining research, while second-tier ones enhance quality of investigations and accelerate understanding of CTR-CVT. Adherence to the proposed quality standards is expected to benefit researchers embarking on new investigations, facilitate funding allocation, and inform the development of novel oncological therapies, eventually moving cardio-oncology science forward.

European Heart Journal
Semmelweis University (HU), University of Pisa (IT), Northwestern University (US), Queen's University Belfast (GB), Belfast Health and Social Care Trust (GB), Beth Israel Deaconess Medical Center (US), University Medical Center Groningen (NL), University of Antwerp (BE), Queen Mary University of London (GB), University of Groningen (NL), German Cancer Research Center (DE), University of Zurich (CH), Heidelberg University (DE), Université Paris-Saclay (FR), Tel Aviv Sourasky Medical Center (IL), Instituto de Salud Carlos III (ES), Erasmus MC (NL), University Hospital Heidelberg (DE), Amsterdam UMC Location University of Amsterdam (NL), Hunter Medical Research Institute (AU), Azienda Mobilità e Trasporti (IT), Ludwig Boltzmann Institute for Age Research (AT), Hospital La Paz Institute for Health Research (ES), Amsterdam Neuroscience (NL), City of Hope (US), Federico II University Hospital (IT), Kantonsspital Baden (CH), German Centre for Cardiovascular Research (DE), Spanish National Centre for Cardiovascular Research (ES), Momentum Research (US), Ludwig Boltzmann Institute Applied Diagnostics (AT), Campus Bio Medico University Hospital (IT), William Harvey Research Institute (GB), Fondation pour l’innovation en Cadiométabolisme et Nutrition (FR), University of Turin (IT), Medical University of Vienna (AT), University of Newcastle Australia (AU), University of Pennsylvania (US), University of Genoa (IT), Newcastle University (GB), University of Amsterdam (NL)
Ministero della Salute
Partnerships for the goals
Openalex Percentile: Top 11%
Chemotherapy-induced cardiotoxicity and mitigation
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.